

Supplementary Table 1. Demographic and clinical comparisons between patients stratified according to the median Brief Resilience Scale (BRS) score (i.e., BRS \leq 2.3 vs. BRS $>$ 2.3)

	Patients with BRS \leq 2.3 (<i>n</i> = 25)	Patients with BRS $>$ 2.3 (<i>n</i> = 25)	<i>p</i>
Age (years)	73.96 \pm 8.66	70.00 \pm 8.436	0.109
Sex (M/F)	15/10	20/5	0.067
Age at onset (years)	67.41 \pm 8.62	63.47 \pm 7.02	0.081
Disease duration (years)	6.55 \pm 3.81	6.52 \pm 4.17	0.976
MDS-UPDRS 3	25.48 \pm 12.83	27.73 \pm 11.61	0.521
HY stage	2.20 \pm 0.71	2.17 \pm 0.46	0.864
Consultation delay due to service shutdown (days)	98.71 \pm 59.58	88.60 \pm 57.59	0.547
COVID-19 related worries	7.44 \pm 1.52	5.91 \pm 2.82	0.018
COVID-19 related worries about health status	8.04 \pm 1.51	6.56 \pm 2.98	0.028
TSQ	2.70 \pm 1.83	1.13 \pm 0.96	0.001
EQ-5D	3.18 \pm 2.20	1.52 \pm 1.73	0.005
EQ-VAS	58.70 \pm 17.89	70.86 \pm 12.49	0.008

Values are expressed as mean \pm standard deviation, unless otherwise specified. **p* < 0.05. BRS: Brief Resilience Scale, EQ-5D: EuroQoL-5 dimensions, EQ-VAS: EuroQoL-visual analogue scale, M: male, F: female, UPDRS: Unified Parkinson's Disease Rating Scale, HY: Hoehn and Yahr, TSQ: Trauma Screening Questionnaire.